Literature DB >> 3802024

Multiple primary neoplasms in association with prostate cancer in black and white patients.

A S Liskow, A I Neugut, M Benson, C A Olsson, J Birkhoff, C H Chang.   

Abstract

The current study follows up the 983 patients who were diagnosed as having prostate cancer at the Columbia-Presbyterian Medical Center in New York City between 1970 and 1979 and of whom 106 (11.5%) developed a multiple primary malignant neoplasm (MPMN) in addition to their prostate cancer by January 1, 1986. Of the 283 black patients, 32 (11.3%) developed an MPMN involving 35 sites excluding prostate. Of the 636 white patients, 74 (11.6%) developed an MPMN in association with their prostate cancer. Comparing observed incidence rates to expected on the basis of SEER incidence data, two malignant tumors, urinary bladder cancer and malignant lymphoma, appeared to occur in excess in the present series of patients. The excess of urinary bladder cancer in our series could be explained by detection bias due to the routine use of cystoscopy. The excess incidence of lymphoma in our series appears significant but its etiology is unexplained.

Entities:  

Mesh:

Year:  1987        PMID: 3802024     DOI: 10.1002/1097-0142(19870115)59:2<380::aid-cncr2820590236>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study.

Authors:  Elizabeth J Davis; Jennifer L Beebe-Dimmer; Cecilia L Yee; Kathleen A Cooney
Journal:  Cancer       Date:  2014-05-19       Impact factor: 6.860

Review 2.  Metachronous multiple primary malignant neoplasms of the stomach and the breast: report of two cases with review of literature.

Authors:  Vilvapathy Senguttuvan Karthikeyan; Sarath Chandra Sistla; Ramachandran Srinivasan; Debdatta Basu; Lakshmi C Panicker; Sheik Manwar Ali; Nagarajan Rajkumar
Journal:  Int Surg       Date:  2014 Jan-Feb

3.  Secondary malignancies following radiotherapy for prostate cancer.

Authors:  Petros Sountoulides; Nikolaos Koletsas; Dimitris Kikidakis; Konstantinos Paschalidis; Nikolaos Sofikitis
Journal:  Ther Adv Urol       Date:  2010-06

4.  Multiple (five) synchronous primary malignant neoplasms of dissimilar histogenesis including a malignant fibrous histiocytoma of the bladder.

Authors:  K Weingärtner; M D Melekos; E W Gerharz; U Köhl; K Neumann; H Riedmiller
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

5.  Multiple primary malignant neoplasms in urologic patients.

Authors:  Osman Inci; Esat Kaya; Bulent Alagol; Irfan Huseyin Atakan; Sabahattin Aydin; Hasan Ereselli
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Bladder cancer following prostate cancer--an analysis of risk factors.

Authors:  H E Wegner; T Meier; R Klän; K P Dieckmann
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

7.  A competing risk analysis of death patterns in male genitourinary cancer.

Authors:  Atanu Bhattacharjee; Gaurav Roy; Atul Budukh; Rajesh Dikshit; Vijay M Patil; Amit Joshi; Vanita Noronha; Kumar Prabash; Papai Roy
Journal:  Cancer Rep (Hoboken)       Date:  2019-04-04

8.  Long-Term Management of Incidental Bladder Cancer Detected in Patients Undergoing Prostatectomy for Prostate Cancer.

Authors:  Norihito Soga; Jun Furusawa; Yuji Ogura
Journal:  Curr Urol       Date:  2019-11-13

9.  Risk of Second Primary Cancer among Prostate Cancer Patients in Korea: A Population-Based Cohort Study.

Authors:  Jae Young Joung; Jiwon Lim; Chang-Mo Oh; Kyu-Won Jung; Hyunsoon Cho; Sung Han Kim; Ho Kyung Seo; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Young-Joo Won
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

10.  Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.

Authors:  Chao-Yueh Fan; Wen-Yen Huang; Chun-Shu Lin; Yu-Fu Su; Cheng-Hsiang Lo; Chih-Cheng Tsao; Ming-Yueh Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.